Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04506086 · ClinicalTrials.gov registry record · Phase 4
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
A Phase 4 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT04506086 is a Phase 4 study that was terminated before completion, run by Amgen. The registered enrollment target is 10 participants.
The verdict
NCT04506086, a Phase 4 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
The study aims to determine the safety and feasibility of complete outpatient blinatumomab administration for subjects with minimal/measurable residual disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL).
Interventions
- DRUG Blinatumomab
- DEVICE Current Wearable Heatlth Monitoring System (CWHMS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-08-26 |
| Est. Completion | 2024-09-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04506086
The ClinicalTrials.gov registry entry for NCT04506086 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Blinatumomab is the first listed.
NCT04506086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04506086 about?
NCT04506086 is a clinical study titled "Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)". The study aims to determine the safety and feasibility of complete outpatient blinatumomab administration for subjects with minimal/measurable residual disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL).
What is the current status of trial NCT04506086?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2021-08-26. Estimated completion is 2024-09-16.
What interventions are being tested in trial NCT04506086?
The interventions under investigation include: Blinatumomab (DRUG), Current Wearable Heatlth Monitoring System (CWHMS) (DEVICE).
Who is sponsoring clinical trial NCT04506086?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.